Wassmer, Evangeline, Billaud, Charly, Absoud, Michael, Abdel-Mannan, Omar, Benetou, Christina, Cummins, Carole, Forrest, Katharine, De Goede, Christian, Eltantawi, Noha, Hickson, Helga, Hussain, Nahin, Jardine, Phil, Livingston, John H., Mordekar, Santosh, Ramdas, Sithara, Taylor, Micheal, Vijayakumar, K., West, Siobhan, Whitehouse, William P., Kneen, Rachel, Hemingway, Cheryl, Lim, Ming, Hacohen, Yael and Wright, Sukhvir (2024). Long term outcome in non-multiple sclerosis paediatric acquired demyelinating syndromes. European Journal of Paediatric Neurology, 52 , pp. 52-58.
Abstract
Objectives: We aimed to study the risks of relapse and long term disability in children with non-MS acquired demyelinating syndromes (ADS). Methods: In this prospective, multi-centre study, from the 14 UK pediatric neurology centres, children (<16 years) experiencing a first episode of ADS were recruited from 2010 to 2014. Case report forms were collected prospectively. Results: A total of 269 children were recruited and followed up for a median of 7.2 years. Median age at onset was 9y (IQR 9.5–14.5, 126 females). At last follow-up, 46 (18 %) had MS, 4 AQP4-Ab NMOSD and 206 (80 %) had other ADS, of which 27 (13 %) relapsed. Relapsing MOGAD was the diagnosis in 12/27, 6 were seronegative and 9 did not have antibodies tested. Frequency of relapse differed according to first presentation in non-MS ADS, being least likely in transverse myelitis (p = 0.025). In the non-MS group, MOG-Ab was predictive of relapse (HR = 8.42; p < 0.001) occurring 8 times as often decreasing over time. Long-term difficulties did not differ between children with monophasic vs relapsing diseases. Conclusion: The risk of relapse in non-MS ADS depends on initial diagnosis, and MOG-Ab positivity. Long-term difficulties are observed regardless of relapses and are determined by presenting phenotype.
Publication DOI: | https://doi.org/10.1016/j.ejpn.2024.07.002 |
---|---|
Divisions: | College of Health & Life Sciences > School of Biosciences College of Engineering & Physical Sciences > School of Infrastructure and Sustainable Engineering > Engineering Systems and Supply Chain Management College of Health & Life Sciences > Aston Pharmacy School College of Health & Life Sciences |
Funding Information: | This study is funded by a grant from the UK Multiple Sclerosis Society (893/08) and Action Medical Research (SP4472). Also, funding was received from Epilepsy Research UK, Encephalitis Society and BCH Charity Research Fund. The protocol was also developed |
Additional Information: | Copyright © 2024. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). |
Uncontrolled Keywords: | AQP4-Ab NMOSD,Acquired demyelinating syndromes,Long term outcomes,MOGAD,Multiple sclerosis,Clinical Neurology,Pediatrics, Perinatology, and Child Health |
Publication ISSN: | 1090-3798 |
Last Modified: | 13 Aug 2024 07:06 |
Date Deposited: | 31 Jul 2024 12:13 |
Full Text Link: |
https://discove ... print/10194412/ |
Related URLs: |
https://linking ... 090379824000990
(Publisher URL) http://www.scop ... tnerID=8YFLogxK (Scopus URL) |
PURE Output Type: | Article |
Published Date: | 2024-09 |
Published Online Date: | 2024-07-06 |
Accepted Date: | 2024-07-02 |
Authors: |
Wassmer, Evangeline
Billaud, Charly Absoud, Michael Abdel-Mannan, Omar Benetou, Christina Cummins, Carole Forrest, Katharine De Goede, Christian Eltantawi, Noha Hickson, Helga Hussain, Nahin Jardine, Phil Livingston, John H. Mordekar, Santosh Ramdas, Sithara Taylor, Micheal Vijayakumar, K. West, Siobhan Whitehouse, William P. Kneen, Rachel Hemingway, Cheryl Lim, Ming Hacohen, Yael Wright, Sukhvir ( ![]() |